Search Within

Mark M Moasser

Formats
  1. Meeting Abstract (32)
  2. Journal Article (24)
Groups
  1. Department of Medicine (44)
  2. Solid Tumor Oncology Division (43)
  3. Breast Medicine Service (41)
  4. GSK Faculty (30)
  5. Molecular Pharmacology and Chemistry Program Faculty (28)
  6. Sloan Kettering Institute Faculty (28)

More Groups

People
  1. Neal Rosen (28)
  2. Clifford Hudis (15)
  3. Larry Norton (14)
  4. Ethan Dmitrovsky (12)
  5. Andrew Seidman (10)
  6. Katherine Panageas (10)

More People

Years
  1. 2008 (2)
  2. 2005 (3)
  3. 2004 (4)
  4. 2003 (8)
  5. 2002 (6)
  6. 2001 (8)

More Years

Publications
  1. Proceedings of the American Association for Cancer Research Annual Meeting (22)
  2. Clinical Cancer Research (8)
  3. Breast Cancer Research and Treatment (6)
  4. Cancer Research (4)
  5. Oncogene (4)
  6. Cancer Investigation (2)

More Publications

Publishers
  1. American Association for Cancer Research (34)
  2. Springer (6)
  3. Nature Publishing Group (5)
  4. American Society of Clinical Oncology (2)
  5. Elsevier Inc. (2)
  6. Informa Healthcare (2)

More Publishers

Results (56)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Inhibition of the PI3 kinase/Akt pathway mediates the antitumor effects of ZD1839 (Iressa) in HER2-overexpressing tumors
    Meeting Abstract

    Basso, A.; Averbuch, S. D.; Rosen, N.; Moasser, M. M.
    Proceedings of the American Association for Cancer Research Annual Meeting (2002)

    Fulltext@MSK | Save
  • A novel class of pyridopyrimidine tyrosine kinase inhibitors blocks cancer cells in the S-phase of the cell cycle
    Meeting Abstract

    Mizenina, O.; Moasser, M.; Rosen, N.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer
    Journal Article

    Moasser, M. M.; Rosen, N.
    Breast Cancer Research and Treatment (2002)

    Fulltext@MSK | Save
  • The tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumors
    Meeting Abstract

    Moasser, M. M.; Basso, A. D.; Averbuch, S. D.; Rosen, N.
    Clinical Cancer Research (2001)

    Fulltext@MSK | Save
  • Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer
    Journal Article

    Sepp-Lorenzino, L.; Tjaden, G.; Moasser, M. M.; Timaul, N.; Ma, Z.; Kohl, N. E.; Gibbs, J. B.; Oliff, A.; Rosen, N.; Scher, H. I.
    Prostate Cancer and Prostatic Diseases (2001)

    Fulltext@MSK | Save
  • Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
    Journal Article

    Seidman, A. D.; Fornier, M. N.; Esteva, F. J.; Tan, L.; Kaptain, S.; Bach, A.; Panageas, K. S.; Arroyo, C.; Valero, V.; Currie, V.; more...
    Journal of Clinical Oncology (2001)

    Fulltext@MSK | Save
  • Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma
    Journal Article

    Fornier, M. N.; Seidman, A. D.; Theodoulou, M.; Moynahan, M. E.; Currie, V.; Moasser, M.; Sklarin, N.; Gilewski, T.; D'Andrea, G.; Salvaggio, R.; more...
    Clinical Cancer Research (2001)

    Fulltext@MSK | Save
  • The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells
    Journal Article

    Moasser, M. M.; Basso, A.; Averbuch, S. D.; Rosen, N.
    Cancer Research (2001)

    Fulltext@MSK | Save
  • Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells
    Journal Article

    Mùˆnster, P. N.; Srethapakdi, M.; Moasser, M. M.; Rosen, N.
    Cancer Research (2001)

    Fulltext@MSK | Save
  • Combined estrogen blockade of the breast with raloxifene and exemestane in postmenopausal women for breast cancer prevention
    Meeting Abstract

    Dickler, M. N.; Robson, M. E.; Heerdt, A.; Dang, C.; Lake, D.; Moasser, M.; Bloch, R.; Ballon, D. J.; Morris, E. A.; Tan, L. K.; more...
    Breast Cancer Research and Treatment (2001)

    Fulltext@MSK | Save